Muscle biopsy substantiates long-term MRI alterations one year after a single dose of botulinum toxin injected into the lateral gastrocnemius muscle of healthy volunteers

Movement Disorders

Volumn 24, Issue 10, 2009, Pages 1494-1503

  Schroeder, A Sebastian ^a   Ertl Wagner, Birgit ^a   Britsch, Stefanie ^a   Schröder, J Michael ^b   Nikolin, Stefan ^b   Weis, Joachim ^b   Müller Felber, Wolfgang ^a   Koerte, Inga ^a   Stehr, Maximilian ^a   Berweck, Steffen ^a   Borggraefe, Ingo ^a   Heinen, Florian ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

Botulinum toxin type A (BoNT A) injection; High signal intensity pattern; Long term neurogenic atrophy; Muscle biopsy; Muscle MRI; Neuromuscular junction

Indexed keywords

BOTULINUM TOXIN A;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEGENERATIVE DISEASE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION ROUTE; DRUG MONITORING; DRUG SAFETY; ELECTRON MICROSCOPY; ENZYME HISTOCHEMISTRY; GASTROCNEMIUS MUSCLE; HEREDITARY MOTOR SENSORY NEUROPATHY; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; IMAGE PROCESSING; MALE; MUSCLE BIOPSY; MUSCLE CELL; NEUROMUSCULAR JUNCTION DISORDER; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REACTION TIME; SIGNAL DETECTION; SINGLE DRUG DOSE; TREATMENT RESPONSE; VOLUNTEER;

ADULT; ANTI-DYSKINESIA AGENTS; BIOPSY; BOTULINUM TOXINS; DOUBLE-BLIND METHOD; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MICROSCOPY, ELECTRON, TRANSMISSION; MIDDLE AGED; MUSCLE, SKELETAL; PROSPECTIVE STUDIES;

EID: 69849105683     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22661     Document Type: Article

References (50)

1. Heinen F, Molenaers G, Fairhurst C, et al. European consensus table 2006 on botulinum toxin for children with cerebral palsy. Eur J Paediatr Neurol 2006;10:215-225.
2. Simpson DM, Blitzer A, Brashear A, et al. Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008;70:1699-1706.
3. Simpson DM, Gracies JM, Graham HK, et al. Assessment: Botulinum neurotoxin for the treatment of spasticity (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008;70:1691-1698.
4. Croes SA, Baryshnikova LM, Kaluskar SS, von Bartheld CS. Acute and long-term effects of botulinum neurotoxin on the function and structure of developing extraocular muscles. Neurobiol Dis 2007;25:649-664.
5. Schroeder AS, Kling T, Borggaefe I, Heinen F, Berweck S. Long-term efficacy of intraglandular botulinum toxin injection to reduce drooling in children with neurological disorders. Dev Med Child Neurol 2008;50 (Suppl 4):42-80.
6. Merati AL, Tseng J, Blumin JH, Toohill RJ, Jaradeh S. Comparative neuromuscular histopathology of cricopharyngeal achalasia patients with and without previous botulinum toxin treatment. Ann Otol Rhinol Laryngol 2007;116:375-380.
7. Fanucci E, Masala S, Sodani G, et al. CT-guided injection of botulinic toxin for percutaneous therapy of piriformis muscle syndrome with preliminary MRI results about denervative process. Eur Radiol 2001;11:2543-2548.
8. Rijsdijk BA, van ER, Zonneveld FW, Steenks MH, Koole R. [Botulinum toxin type A treatment of cosmetically disturbing masseteric hypertrophy]. Ned Tijdschr Geneeskd 1998;142:529-532.
9. Kim JH, Shin JH, Kim ST, Kim CY. Effects of two different units of botulinum toxin type a evaluated by computed tomography and electromyographic measurements of human masseter muscle. Plast Reconstr Surg 2007;119:711-717.
10. Costa J, Graca P, Evangelista T, de Carvalho M. Pain and calf hypertrophy associated with spontaneous repetitive discharges treated with botulinum toxin. Clin Neurophysiol 2005;116:2847-2852.
11. Haferkamp A, Schurch B, Reitz A, et al. Lack of ultrastructural detrusor changes following endoscopic injection of botulinum toxin type a in overactive neurogenic bladder. Eur Urol 2004;46:784-791.
12. Schulte-Baukloh H, Knispel HH. A minimally invasive technique for outpatient local anaesthetic administration of intradetrusor botulinum toxin in intractable detrusor overactivity. BJU Int 2005;95:454.
13. Han KH, Joo YH, Moon SE, Kim KH. Botulinum toxin A treatment for contouring of the lower leg. J Dermatolog Treat 2006; 17:250-254.
14. Levy JL, Pons F, Jouve E. Management of the ageing eyebrow and forehead: an objective dose-response study with botulinum toxin. J Eur Acad Dermatol Venereol 2006;20:711-716.
15. Naumann M, Albanese A, Heinen F, Molenaers G, Relja M. Safety and efficacy of botulinum toxin type A following long-term use. Eur J Neurol 2006;13 (Suppl 4):35-40.
16. Wohlfarth K, Muller C, Sassin I, Comes G, Grafe S. Neurophysiological double-blind trial of a botulinum neurotoxin type a free of complexing proteins. Clin Neuropharmacol 2007;30:86-94.
17. Fanucci E, Masala S, Squillaci E, et al. Pyriformis muscle syndrome: CT/ MR findings in the percutaneous therapy with botulinic toxin. Radiol Med (Torino) 2003;105:69-75.
18. Hassan SM, Jennekens FG, Veldman H. Botulinum toxin-induced myopathy in the rat. Brain 1995;118 (Part 2):533-545.
19. Rosales RL, Arimura K, Takenaga S, Osame M. Extrafusal and intrafusal muscle effects in experimental botulinum toxin-A injection. Muscle Nerve 1996;19:488-496.
20. Lu L, Atchabahian A, Mackinnon SE, Hunter DA. Nerve injection injury with botulinum toxin. Plast Reconstr Surg 1998;101: 1875-1880.
21. Neale EA, Bowers LM, Jia M, Bateman KE, Williamson LC. Botulinum neurotoxin A blocks synaptic vesicle exocytosis but not endocytosis at the nerve terminal. J Cell Biol 1999;147: 1249-1260.
22. Chen CM, Stott NS, Smith HK. Effects of botulinum toxin A injection and exercise on the growth of juvenile rat gastrocnemius muscle. J Appl Physiol 2002;93:1437-1447.
23. Shen J, Ma J, Lee C, et al. How muscles recover from paresis and atrophy after intramuscular injection of botulinum toxin A: study in juvenile rats. J Orthop Res 2006;24:1128-1135.
24. Choi WH, Song CW, Kim YB, et al. Skeletal muscle atrophy induced by intramuscular repeated dose of botulinum toxin type A in rats. Drug Chem Toxicol 2007;30:217-227.
25. Minamoto VB, Hulst JB, Lim M, et al. Increased efficacy and decreased systemic-effects of botulinum toxin A injection after active or passive muscle manipulation. Dev Med Child Neurol 2007;49:907-914.
26. Pamphlett R. Early terminal and nodal sprouting of motor axons after botulinum toxin. J Neurol Sci 1989;92:181-192.
27. Juzans P, Comella JX, Molgo J, Faille L, Angaut-Petit D. Nerve terminal sprouting in botulinum type-A treated mouse levator auris longus muscle. Neuromuscul Disord 1996;6:177-185.
28. de Paiva A, Meunier FA, Molgo J, Aoki KR, Dolly JO. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci USA 1999;96:3200-3205.
29. Elmas C, Ayhan S, Tuncer S, et al. Effect of fresh and stored botulinum toxin a on muscle and nerve ultrastructure: an electron microscopic study. Ann Plast Surg 2007;59:316-322.
30. Harrison AR, Anderson BC, Thompson LV, McLoon LK. Myofiber length and three-dimensional localization of NMJs in normal and botulinum toxin treated adult extraocular muscles. Invest Ophthalmol Vis Sci 2007;48:3594-3601.
31. Pastor AM, Moreno-Lopez B, De La Cruz RR, Delgado-Garcia JM. Effects of botulinum neurotoxin type A on abducens moto-neurons in the cat: ultrastructural and synaptic alterations. Neuroscience 1997;81:457-478.
32. Spencer RF, McNeer KW. Botulinum toxin paralysis of adult monkey extraocular muscle. Structural alterations in orbital, singly innervated muscle fibers. Arch Ophthalmol 1987;105:1703-1711.
33. Capra NF, Bernanke JM, Porter JD. Ultrastructural changes in the masseter muscle of Macaca fascicularis resulting from intra-muscular injections of botulinum toxin type A. Arch Oral Biol 1991;36:827-836.
34. Borodic GE, Ferrante R. Effects of repeated botulinum toxin injections on orbicularis oculi muscle. J Clin Neuro-Ophthalmol 1992;12:121-127.
35. Holds JB, Alderson K, Fogg SG, Anderson RL. Motor nerve sprouting in human orbicularis muscle after botulinum A injection. Invest Ophthalmol Vis Sci 1990;31:964-967.
36. Schröder JM, Huffmann B, Braun V, Richter HP. Spasmodic torticollis: severe compression neuropathy in rami dorsales of cervical nerves C1-6. Acta Neuropathol (Berl) 1992;84:416-424.
37. Schulte-Baukloh H, Zurawski TH, Knispel HH, Miller K, Haferkamp A, Dolly JO. Persistence of the synaptosomal-associated protein-25 cleavage product after intradetrusor botulinum toxin A injections in patients with myelomeningocele showing an inadequate response to treatment. BJU Int 2007;100:1075-1080.
38. WeMove. Management of spasticity with Botulinum toxin type A (Botox) - suggested adult Botox dosing, Third ed. WeMove; 2005. Available at http://www.mdvu.org.
39. Lakadamyali H, Tarhan NC, Ergun T, Cakir B, Agildere AM. STIR sequence for depiction of degenerative changes in posterior stabilizing elements in patients with lower back pain. AJR Am J Roentgenol 2008;191:973-979.
40. Mayer EJ, Fox DL, Herdman G, et al. Signal intensity, clinical activity and cross-sectional areas on MRI scans in thyroid eye disease. Eur J Radiol 2005;56:20-24.
41. Gaeta M, Mazziotti S, Minutoli F, et al. MR imaging findings of focal myositis: a pseudotumour that may mimic muscle neoplasm. Skeletal Radiol 2009;38:571-578.
42. Walker UA. Imaging tools for the clinical assessment of idiopathic inflammatory myositis. Curr Opin Rheumatol 2008;20: 656-661.
43. Gallardo E, Claeys KG, Nelis E, et al. Magnetic resonance imaging findings of leg musculature in Charcot-Marie-Tooth disease type 2 due to dynamin 2 mutation. J Neurol 2008;255:986-992.
44. Connor A, Stebbings S, Anne Hung N, Hammond-Tooke G, Meikle G, Highton J. STIR MRI to direct muscle biopsy in suspected idiopathic inflammatory myopathy. J Clin Rheumatol 2007;13:341-345.
45. Schurch B, Hodler J, Rodic B. Botulinum A toxin as a treatment of detrusor-shincter dyssynergia in patients with spinal cord injury: MRI controlled transperineal injections. J Neurol Neurosurg Psychiatr 1997;63:474-476.
46. Kamath S, Venkatanarasimha N, Walsh MA, Hughes PM. MRI appearance of muscle denervation. Skeletal Radiol 2008;37:397-404.
47. Duchen LW. Changes in motor innervation and cholinesterase localization induced by botulinum toxin in skeletal muscle of the mouse: differences between fast and slow muscles. J Neurol Neurosurg Psychiatry 1970;33:40-54.
48. Jost WH, Kohl A, Brinkmann S, Comes G. Efficacy and tolerability of a botulinum toxin type A free of complexing proteins (NT 201) compared with commercially available botulinum toxin type A (BOTOX) in healthy volunteers. J Neural Transm 2005; 112:905-913.
49. Hunt T, Clarke K. Potency evaluation of a formulated drug product containing 150-kd botulinum neurotoxin type A. Clin Neuropharmacol 2008.
50. Gottlieb SL, Kretsinger K, Tarkhashvili N, et al. Long-term outcomes of 217 botulism cases in the Republic of Georgia. Clin Infect Dis 2007;45:174-180.